We found that Ag+ CD4+ T cells from IFN-treated patients displayed a higher glucose dependence when compared to HD, while natalizumab-treated patients displayed the highest glycolytic capacity (Supplementary Fig. 20). The gene discussed is RENBP; the disease is Huntington disease.